One such novel compound, 2-hydroxy-5-[2-(4-trifluromethylphenyl)-ethylaminobenzoic acid] (AAD-2004) has been utilized in SOD1 transgenic mice to combat the inflammatory sequelae of ALS. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.